Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Anastrozole and Ezetimibe Interaction: Avoid | Peptide Database

Compound Profiles Anastrozole Aromatase Inhibitor | Estrogen Management Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Anastrozole

Aromatase Inhibitor | Estrogen Management

Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Ezetimibe

Cholesterol Absorption Inhibitor | Lipid Management On Cycle

Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Anastrozole with Ezetimibe?

Combining Anastrozole with Ezetimibe is not recommended. Both Anastrozole and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Anastrozole and Ezetimibe safe together?

This combination carries significant risk. Both Anastrozole and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Anastrozole and Ezetimibe?

Both Anastrozole and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anastrozole and Ezetimibe?

Anastrozole has a half-life of ~40-50 hours and Ezetimibe has a half-life of ~22 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Finasteride — share findings, ask questions, and learn from real experiences Finasteride is an FDA-approved 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgen responsible for androgenetic alopecia (male pattern hair loss) and benign prostatic hyperplasia (BPH). At 1mg daily, it reduces scalp DHT levels by approximately 66%, slowing or halting hair loss in roughly 90% of men and producing visible regrowth in about 48% over one to two years. Originally developed for prostate enlargement at 5mg (Proscar), the lower 1mg dose (Propecia) was approved specifically for hair loss in 1997. It remains one of only two FDA-approved oral treatments for androgenetic alopecia and has decades of long-term safety data. Finasteride competitively and selectively inhibits the Type II isoform of the enzyme 5-alpha reductase, which is predominantly found in hair follicles, the prostate, and the liver. This enzyme converts testosterone into dihydrotestosterone (DHT). By blocking this conversion, finasteride reduces serum DHT levels by approximately 70% and scalp DHT by roughly 66% at the 1mg dose. Since DHT is the primary androgen driving miniaturization of hair follicles in genetically susceptible individuals, lowering DHT levels allows affected follicles to recover, extend the anagen (growth) phase, and produce thicker terminal hairs. Notably, finasteride does not block androgen receptors and has minimal effect on testosterone levels, which may increase slightly (by about 10-15%) as a compensatory response to reduced DHT.

Source: peptide-db.com ↗

Research Indications

Used as a diagnostic agent in Japan for assessing growth hormone deficiency in clinical settings. Stimulates endogenous growth hormone release through ghrelin receptor activation. Indirectly increases IGF-1 levels through enhanced GH secretion. Enhanced muscle protein synthesis through elevated growth hormone and IGF-1 levels. Improved lipolysis and body composition through GH-mediated fat oxidation. Faster recovery from exercise and improved sleep quality. Myoprotective effects in muscle atrophy models through GHS-R1a stimulation. Cytoprotective effects observed in cardiac tissue research.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Available in capsule form for oral administration. As a tripeptide, Chonluten has favorable permeability across cellular compartments. Typical protocol involves 10-20 day cycles. Standard protocol 10-20 mg Daily for 10-20 days Oral capsules Maintenance 10 mg 2-3 cycles yearly

Source: peptide-db.com ↗
Side effects

Does EPO improve endurance without causing side effects?

EPO absolutely improves endurance capacity by increasing red blood cell production and oxygen delivery. However, it commonly causes water retention, joint pain, headaches, and hypertension. More concerning are thromboembolic events (blood clots) and theoretical tumor progression risk with higher doses used for performance enhancement.

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides